Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)
Salvage chemotherapy with XELOX may offer clinical benefits for patients with metastatic or advanced gastric cancer resistant to or intolerant of cisplatin.
Authors
- Hisato Kawakami (ORCID: https://orcid.org/0000-0002-3280-4850)
- Daisuke Sakai (ORCID: https://orcid.org/0000-0001-5538-4927)
- Shuhei Ueda (ORCID: https://orcid.org/0000-0001-8107-8608)
- Kohei Murakami (ORCID: https://orcid.org/0000-0001-5458-410X)
- Yukinori Kurokawa (ORCID: https://orcid.org/0000-0002-2883-0132)
- Shunji Endo (ORCID: https://orcid.org/0000-0003-0720-4156)
- Taroh Satoh (ORCID: https://orcid.org/0000-0002-4615-2638)
- Kazumasa Fujitani (ORCID: https://orcid.org/0000-0003-4954-5047)
- Toshio Shimokawa (ORCID: https://orcid.org/0000-0002-2256-0282)
- Naotoshi Sugimoto (ORCID: https://orcid.org/0000-0003-1995-5002)
- Kazuhiro Nishikawa (ORCID: https://orcid.org/0000-0003-1213-2732)
- Junji Kawada
- Yoshio Oka
Institutions
- Kawasaki Medical School (JP)
- Wakayama Medical University (JP)
- Tohoku University (JP)
- Osaka Prefectural Medical Center (JP)
- Osaka National Hospital (JP)
- Osaka City General Hospital (JP)
- Kansai Rosai Hospital (JP)
- Nagahama City Hospital (JP)
- Osaka International Cancer Institute (JP)
- Takarazuka City Hospital (JP)
- Osaka University Hospital (JP)
- Kitano Hospital (JP)
- Minoh City Hospital (JP)
- Osaka International University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.21873/anticanres.17418
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00